Investment Thesis
Galectin Therapeutics is a pre-revenue pharmaceutical company with severe financial distress, negative stockholders' equity of -$125.3M, and massive ongoing cash burn of -$17.8M annually. The company lacks meaningful revenue generation, has only 11.5M in cash reserves against 136.4M in liabilities, and faces imminent liquidity crisis with a current ratio of 0.09x.
Strengths
- Maintains some cash reserves of $11.5M for near-term operations
- Relatively low capital expenditure requirements typical for biotech R&D stage
- Active insider trading activity (19 Form 4 filings in 90 days) suggests ongoing leadership engagement
Risks
- Negative stockholders' equity of -$125.3M indicates technical insolvency
- Severe liquidity crisis with current ratio of 0.09x and minimal cash relative to liabilities
- Continuous operating losses of -$17.8M annually with zero revenue generation creates unsustainable cash burn trajectory
- Liabilities of $136.4M vastly exceed total assets of $12.9M with no clear path to profitability
- Pre-revenue stage with no demonstrated commercial viability or product revenue
Key Metrics to Watch
- Cash balance depletion rate and runway months remaining
- Progress toward clinical trial endpoints and regulatory approvals
- Quarterly operating cash burn trends and cost reduction measures
- Debt restructuring negotiations or capital raise announcements
- Pipeline advancement and licensing/partnership deals to generate revenue
Financial Metrics
Revenue
N/A
Net Income
-25.3M
EPS (Diluted)
$-0.40
Free Cash Flow
-17.8M
Total Assets
12.9M
Cash
11.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-196.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.09x
Quick Ratio
0.09x
Debt/Equity
N/A
Debt/Assets
1,060.6%
Interest Coverage
-15.89x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-25T13:04:10.950716 |
Data as of: 2025-09-30 |
Powered by Claude AI